Insulet (PODD) Common Equity (2010 - 2026)

Insulet has reported Common Equity for 17 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 2.1% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 2.1% YoY), and the FY2025 full-year result was $1.5 billion, up 25.06% from the prior year.
• Common Equity for Q1 2026 stood at $1.3 billion, down from $1.5 billion in the prior quarter.
• The five-year high for Common Equity was $1.5 billion in Q4 2025, with the low at $422.4 million in Q2 2022.
• Historically, Common Equity has averaged $899.1 million across 5 years, with a median of $790.7 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity declined 23.68% — and 2024, when it soared 84.03%.
• Insulet's Common Equity stood at $476.4 million in 2022, then jumped by 53.8% to $732.7 million in 2023, then jumped by 65.36% to $1.2 billion in 2024, then climbed by 25.06% to $1.5 billion in 2025, then dropped by 14.03% to $1.3 billion in 2026.
• The last three Common Equity figures came in at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.